Real-World Comparative Effectiveness of Deucravacitinib vs Apremilast at 6 Months for Plaque Psoriasis: Skin Clearance Outcomes From the RePhlect Study

Main Article Content

April W. Armstrong
University of California Los Angeles, Los Angeles, California, USA

Mark Lebwohl
Icahn School of Medicine at Mount Sinai, New York, New York, USA

Swetha Srinivasan
Bristol Myers Squibb, Princeton, New Jersey, USA

Joe Zhuo
Bristol Myers Squibb, Princeton, New Jersey, USA

Yichen Zhong
Bristol Myers Squibb, Princeton, New Jersey, USA

Melinda Gooderham
SKiN Centre for Dermatology, Peterborough, Ontario, Canada

Adam Sima
Thermo Fisher Scientific , Waltham, Massachusetts, USA

Robert R. McLean
Thermo Fisher Scientific , Waltham, Massachusetts, USA

Kim A. Papp
Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada and the Division of Dermatology, Temerty School of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada

Joseph F. Merola
University of Texas Southwestern Medical Center, Dallas, Texas, USA

Alice B. Gottlieb
University of Texas Southwestern Medical Center, Dallas, Texas, USA

Stefan Varga
Bristol Myers Squibb, Princeton, New Jersey, USA

Bruce Strober
Yale University School of Medicine, New Haven, Connecticut, USA, and Central Connecticut Dermatology Research, Cornwell, Connecticut, USA

Keywords

real-world effectivness, deucravacitinib, skin clearance

References

N/A

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/9zz14r68

Article Details

How to Cite
1.
Real-World Comparative Effectiveness of Deucravacitinib vs Apremilast at 6 Months for Plaque Psoriasis: Skin Clearance Outcomes From the RePhlect Study. J of Skin. 2025;9(6):s651. doi:10.25251/9zz14r68
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)